*The search scope is limited to the products and news section of this site
*The search scope is limited to the products and news section of this site
The company's manufacturing site passed the GMP compliance inspection successfully in May 2022. It is a sign that the company can manufacture and operate pharmaceutical products in compliance.
Responding to market demand, Genuine Biotech has devoted full efforts to enhancing production capacity, and now the company has achieved a leap to an annual capacity of 3 billion tablets. This significant enhancement in production capability lays a solid foundation for the commercialization of innovative products.
The manufacturing facility was designed and built for azvudine and other drug candidates, coving the whole manufacturing cycle, including production, dosing, filling, packaging and quality assurance to support the in-house production.
Copyright © 2022 河南真实生物科技有限公司 All Rights Reserved 京ICP备2021026784号-1
